Henry Schein Q3 sales slightly miss, raises 2026 profit outlook
Overview
Healthcare distributor's Q3 sales rose 4%, slightly missing analyst expectations
Adjusted EPS for Q3 rose 13%, beating analyst expectations
Company raised FY2026 guidance for non-GAAP EPS and adjusted EBITDA
Outlook
Company raises FY2026 non-GAAP diluted EPS guidance to $5.50-$5.56 from $5.29-$5.39
Henry Schein maintains FY2026 total sales growth outlook at 4.5%-5.5%
Company now expects FY2026 Adjusted EBITDA growth in high-single-digits, up from mid to high-single-digits
Result Drivers
DENTAL MERCHANDISE VOLUME - Co said 8.6% growth in U.S. dental merchandise sales was primarily driven by higher volume and market share gains, per CEO Fred Lowery
MARKET SHARE GAINS - Co attributed results to gaining share in key businesses and improved portfolio mix, per CEO Fred Lowery
TARIFF REFUND BENEFIT - Co said Q3 results included net benefit from tariff refunds
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Slight Miss* | $3.47 bln | $3.48 bln (14 Analysts) |
Q3 Adjusted EPS | Beat | $1.56 | $1.36 (16 Analysts) |
Q3 EPS | $1.06 | ||
Q3 Adjusted Net Income | Beat | $175 mln | $154.13 mln (10 Analysts) |
Q3 Net Income | $119 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Henry Schein, Inc. is $95.11, about 9.8% above its November 2 closing price of $86.62
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 3 - Fresenius Medical cuts 2026 profit outlook as US treatment decline deepens
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)